OpportunityTitle: Limited Competition: AIDS Malignancy Clinical Trials Consortium (UM1)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following: Only the current awardees of the AIDS Malignancy Consortium are eligible to apply to this FOA.
Description: The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of the AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international importance in HIV-associated-malignancies; and 5) distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. In addition, the AMC is expected to continue the development and execution of the &quot;ANCHOR&quot; study on the treatment of anal cancer high-grade squamous intraepithelial lesions (HSIL) to reduce anal cancer. In the current funding period, the initiation of the ANCHOR study was supported through supplemental funding to AMC. The Consortium will consist of a coordinating center, clinical trials sites, network laboratories, and a statistical center. The Consortium will have at least four scientific disease-oriented Working Groups (WGs): 1) Kaposi sarcoma WG; 2) lymphoma WG; 3) WG for human papilloma virus-associated cancers; and 4) WG for non-AIDS-Defining Cancers.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;